Hsa-circ-0006091 modulates the proliferation of hepatocellular carcinoma via the miR-622/CCNB1 axis.

Publisher: Scientific and Technical Research Council of Turkey Country of Publication: Turkey NLM ID: 9441758 Publication Model: eCollection Cited Medium: Internet ISSN: 1303-6165 (Electronic) Linking ISSN: 13000144 NLM ISO Abbreviation: Turk J Med Sci Subsets: MEDLINE

Original Publication: Ankara : Scientific and Technical Research Council of Turkey, [1994-

Carcinoma, Hepatocellular*/genetics ; Carcinoma, Hepatocellular*/pathology ; Carcinoma, Hepatocellular*/metabolism ; Cell Proliferation*/genetics ; Cyclin B1*/metabolism ; Cyclin B1*/genetics ; Liver Neoplasms*/genetics ; Liver Neoplasms*/pathology ; Liver Neoplasms*/metabolism ; MicroRNAs*/genetics ; MicroRNAs*/metabolism ; RNA, Circular*/genetics ; RNA, Circular*/metabolism; Animals ; Humans ; Mice ; Cell Line, Tumor ; Gene Expression Regulation, Neoplastic ; Matrix Metalloproteinase 9/metabolism ; Matrix Metalloproteinase 9/genetics

Background/aim: Hepatocellular carcinoma (HCC) is a common type of cancer. We hypothesize that circular RNA-0006091 (circ-0006091) affects the progression of HCC. The study aims to investigate the effect of circ-0006091 in HCC cells.
Materials and Methods: The levels of circ-0006091, microRNA-622 (miR-622), and cyclin B1 (CCNB1) were assayed using qRT-PCR and western blotting. The metastasis of the HCC cells was measured with wound healing and transwell assays. The protein expression levels of MMP-2 and MMP-9 were assayed with western blotting. Dual-luciferase reporter and RNA-pulldown assays were used to determine the link between miR-622 and circ-0006091 or CCNB1. Mice-based tests were used to determine the effect of circ-0006091 on the proliferation of HCC cells.
Results: The levels of circ-0006091 and CCNB1 were increased in the HCC cells, but miR-622 was down-regulated. Deficiency of circ-0006091 reduced the metastasis of the HCC cells, and silencing of circ-0006091 decreased the activities of MMP-2 and MMP-9 in the same cells. Circ-0006091 modulated the CCNB1 level in the HCC cells via miR-622. Silencing of circ-0006091 suppressed the proliferation of the HCC cells in vivo.
Conclusion: Circ-0006091 regulated HCC cell metastasis via the miR-622/CCNB1 axis, a possible therapeutic target in managing HCC.
Competing Interests: Conflict of interest: All authors declared that they have no conflicts of interest.
(© TÜBİTAK.)

Nat Commun. 2015 Sep 25;6:8494. (PMID: 26404566)
Cell Death Discov. 2021 Oct 1;7(1):270. (PMID: 34599150)
Cell Death Dis. 2021 Jul 9;12(7):691. (PMID: 34244479)
Mol Oncol. 2017 Apr;11(4):422-437. (PMID: 28211215)
Cell Transplant. 2019 Dec;28(1_suppl):76S-86S. (PMID: 31822116)
Hepatology. 2020 Jan;71(1):130-147. (PMID: 31148183)
J Gastrointest Oncol. 2017 Apr;8(2):256-265. (PMID: 28480065)
Dis Markers. 2022 Jul 14;2022:9616764. (PMID: 35872695)
Hepatology. 2018 Jan;67(1):358-380. (PMID: 28130846)
Front Oncol. 2021 Sep 30;11:738841. (PMID: 34660300)
J Cell Physiol. 2018 Jan;234(1):619-631. (PMID: 30069972)
Cancer Biol Ther. 2015;16(12):1754-63. (PMID: 26467022)
Oncol Res. 2021 Sep 7;28(7):835. (PMID: 34503611)
World J Gastroenterol. 2014 May 28;20(20):5935-50. (PMID: 24876717)
Am J Cancer Res. 2017 Jul 01;7(7):1566-1576. (PMID: 28744405)
Cell Death Dis. 2020 Dec 14;11(12):1065. (PMID: 33311442)
Bioengineered. 2022 Feb;13(2):1988-2003. (PMID: 35068348)
Andrologia. 2021 Oct;53(9):e14174. (PMID: 34231241)
Int J Mol Sci. 2016 Oct 13;17(10):. (PMID: 27754357)
Dig Dis. 2016;34(5):597-602. (PMID: 27332893)
Cancer Cell Int. 2020 Aug 25;20:404. (PMID: 32863763)
Eur Rev Med Pharmacol Sci. 2017 Dec;21(23):5342-5352. (PMID: 29243777)
Mol Oncol. 2020 Jun;14(6):1365-1380. (PMID: 31944556)
Dig Dis Sci. 2021 Dec;66(12):4384-4397. (PMID: 33433806)
Br J Cancer. 2020 Aug;123(3):426-437. (PMID: 32418991)
Naunyn Schmiedebergs Arch Pharmacol. 2020 Mar;393(3):359-370. (PMID: 31637455)
Biochem Biophys Res Commun. 2020 Dec 17;533(4):845-852. (PMID: 33008587)
Eur Rev Med Pharmacol Sci. 2019 Mar;23(5):2084-2091. (PMID: 30915753)
J Hepatol. 2018 Jun;68(6):1214-1227. (PMID: 29378234)
Oncotarget. 2017 Apr 6;8(35):58405-58416. (PMID: 28938566)
Cancer Lett. 2020 Apr 10;475:119-128. (PMID: 32014458)
Med Sci Monit. 2020 Aug 31;26:e925289. (PMID: 32863381)
Immunol Cell Biol. 2019 Feb;97(2):218-228. (PMID: 30302825)
Life Sci. 2020 Sep 15;257:118082. (PMID: 32653519)
Int J Environ Res Public Health. 2021 Jun 04;18(11):. (PMID: 34199687)
J Exp Clin Cancer Res. 2018 Nov 29;37(1):294. (PMID: 30486894)
Gene. 2019 May 30;699:37-42. (PMID: 30851425)
J Hepatol. 2019 Apr;70(4):674-683. (PMID: 30543829)
Adv Ther. 2008 Nov;25(11):1089-104. (PMID: 18972075)
J Hepatol. 2018 Mar;68(3):526-549. (PMID: 28989095)
Exp Biol Med (Maywood). 2022 Mar;247(5):395-408. (PMID: 34743578)
Methods Enzymol. 2006;407:597-612. (PMID: 16757355)
Trends Biochem Sci. 2005 Nov;30(11):630-41. (PMID: 16236519)
Tumour Biol. 2017 Jul;39(7):1010428317709991. (PMID: 28695772)

Keywords: Hepatocellular carcinoma; circ-0006091; cyclin B1; invasion; miR-622; migration

0 (CCNB1 protein, human)
0 (Cyclin B1)
EC 3.4.24.35 (Matrix Metalloproteinase 9)
0 (MicroRNAs)
0 (RNA, Circular)
0 (MIRN622 microRNA, human)

Date Created: 20240530 Date Completed: 20240530 Latest Revision: 20240606

20240606

PMC10763780

10.55730/1300-0144.5703

38813026